HK1050321A1 - Treatment of cartilage disorders - Google Patents

Treatment of cartilage disorders

Info

Publication number
HK1050321A1
HK1050321A1 HK03102436A HK03102436A HK1050321A1 HK 1050321 A1 HK1050321 A1 HK 1050321A1 HK 03102436 A HK03102436 A HK 03102436A HK 03102436 A HK03102436 A HK 03102436A HK 1050321 A1 HK1050321 A1 HK 1050321A1
Authority
HK
Hong Kong
Prior art keywords
igf
treatment
cartilage
igfbp
cartilage disorders
Prior art date
Application number
HK03102436A
Other languages
English (en)
Inventor
Yves Dubaquie
Ellen H Filvaroff
Henry B Lowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1050321A1 publication Critical patent/HK1050321A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03102436A 2000-05-16 2003-04-04 Treatment of cartilage disorders HK1050321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20449000P 2000-05-16 2000-05-16
US24898500P 2000-11-15 2000-11-15
PCT/US2001/015904 WO2001087323A2 (en) 2000-05-16 2001-05-16 Method for treating cartilage disorders

Publications (1)

Publication Number Publication Date
HK1050321A1 true HK1050321A1 (en) 2003-06-20

Family

ID=26899527

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102436A HK1050321A1 (en) 2000-05-16 2003-04-04 Treatment of cartilage disorders

Country Status (9)

Country Link
US (4) US20030069177A1 (xx)
EP (1) EP1282437B1 (xx)
AT (1) ATE389416T1 (xx)
AU (1) AU2001263215A1 (xx)
DE (1) DE60133271T2 (xx)
DK (1) DK1282437T3 (xx)
ES (1) ES2301547T3 (xx)
HK (1) HK1050321A1 (xx)
WO (1) WO2001087323A2 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1099443A1 (en) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplant/implant device and method for its production
US7387889B2 (en) * 2002-08-22 2008-06-17 Massachusetts Institute Of Technology Measurement of concentrations and binding energetics
ES2405080T3 (es) * 2003-02-26 2013-05-30 Zimmer Orthobiologics, Inc. Preparado para la reparación de un tejido cartilaginoso, en particular de defectos de cartílagos articulares
US20070275032A1 (en) * 2004-03-05 2007-11-29 Synthes (U.S.A.) Use Of A Mixture For The Production Of An Agent For Treating Defective Or Degenerated Cartilage In The Production Of Natural Cartilage Replacement In Vitro
US20080031819A1 (en) * 2004-06-09 2008-02-07 Beth Israel Deaconess Medical Center Compositions and Methods that Enhance Articular Cartilage Repair
EP1764117A1 (en) 2005-09-20 2007-03-21 Zimmer GmbH Implant for the repair of a cartilage defect and method for manufacturing the implant
EP3146939B1 (en) 2006-02-07 2018-09-05 Spinalcyte, LLC Composition for repair of cartilage using an in vivo bioreactor
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CA2674209A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
BRPI0920030B1 (pt) * 2008-10-06 2019-03-26 3-D Matrix, Ltd. Agente de oclusão do tecido, agentes hemostáticos, preventivos e de oclusão ou escleroterapia relacionados, e infusão do tecido mucosal
ES2773766T3 (es) 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
ES2653679T3 (es) * 2011-11-09 2018-02-08 Spinalcyte, Llc Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
US10793307B2 (en) 2012-07-06 2020-10-06 3-D Matrix, Ltd. Fill-finish process for peptide solutions
US10206954B2 (en) 2013-06-19 2019-02-19 Spinalcyte, Llc Adipose cells for chondrocyte applications
EP3466965A1 (en) 2014-03-10 2019-04-10 3-D Matrix Ltd. Self-assembling peptide compositions
CN106456811B (zh) 2014-03-10 2021-04-02 三维矩阵有限责任公司 肽组合物的灭菌和过滤
ES2712608T3 (es) 2014-03-10 2019-05-14 3 D Matrix Ltd Péptidos autoensamblantes para el tratamiento de las bullas pulmonares
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
US11324703B2 (en) 2017-12-15 2022-05-10 3-D Matrix, Ltd. Surfactant peptide nanostructures and uses thereof in drug delivery

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4444047A (en) * 1979-06-29 1984-04-24 Vdo Adolf Schindling A.G. Apparatus for determining the fuel consumption of injection internal combustion engines
NO154236C (no) 1979-07-16 1986-08-20 Ciba Geigy Ag Etterbehandling av med flammebeskyttelsesmiddel behandlede, celluloseholdige fibermaterialer med flytende ammoniakk.
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
WO1987001038A1 (en) 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (en) 1987-04-23 1994-08-10 Monsanto Company Secretion of insulin-like growth factor 1 in E. coli
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
EP0327503B1 (en) 1988-02-05 1993-03-10 Ciba-Geigy Ag Use of igf i in the manufacture of a medicament for the treatment of renal diseases
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0418230B1 (en) 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0379338A3 (en) 1989-01-17 1991-07-24 Merck & Co. Inc. Human insulin-like growth factor analogs and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DK0597033T3 (da) 1991-08-01 1997-06-02 Genentech Inc IGF-1 til forbedring af den neurale tilstand
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (xx) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
CA2136969C (en) 1992-06-12 2009-03-24 Michael E. Lewis Prevention and treatment of peripheral neuropathy
GB9217696D0 (en) 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
EP0642350A4 (en) 1993-01-25 1995-06-28 Beth Israel Hospital PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS.
CA2154078A1 (en) 1993-01-29 1994-08-04 George N. Cox Wound healing composition
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5767085A (en) 1993-12-23 1998-06-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5712249A (en) 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5596844A (en) * 1995-02-03 1997-01-28 Kalinowski; Juan R. Foldable portable building
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
AU697119B2 (en) 1995-05-26 1998-09-24 Theratechnologies Inc. Chimeric fatty body-pro-GRF analogs with increased biological potency
ES2303338T3 (es) 1995-06-07 2008-08-01 Glaxo Group Limited Peptidos y compuestos que se unen a un receptor de trombopoyetina.
WO1996040189A1 (en) 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US5985830A (en) 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
IL129772A0 (en) 1996-11-06 2000-02-29 Genentech Inc Constrained helical peptides and methods of making same
CA2276049A1 (en) 1996-12-27 1998-07-09 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
JP2002510646A (ja) * 1998-04-03 2002-04-09 カイロン コーポレイション 関節軟骨障害を処置するためのｉｇｆｉの使用
ATE303159T1 (de) 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2000069901A2 (en) 1999-05-19 2000-11-23 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
EP2368902A3 (en) 2000-03-29 2011-12-21 DGI Bio Technologies LLC Insulin and IGF-1 receptor agonists and antagonists

Also Published As

Publication number Publication date
WO2001087323A2 (en) 2001-11-22
US20100130411A1 (en) 2010-05-27
WO2001087323A3 (en) 2002-04-11
DE60133271T2 (de) 2009-04-23
ES2301547T3 (es) 2008-07-01
US20090011988A1 (en) 2009-01-08
US20030069177A1 (en) 2003-04-10
US8110548B2 (en) 2012-02-07
US20030211992A1 (en) 2003-11-13
DE60133271D1 (de) 2008-04-30
EP1282437B1 (en) 2008-03-19
AU2001263215A1 (en) 2001-11-26
EP1282437A2 (en) 2003-02-12
DK1282437T3 (da) 2008-06-30
US7947650B2 (en) 2011-05-24
ATE389416T1 (de) 2008-04-15
US7423017B2 (en) 2008-09-09

Similar Documents

Publication Publication Date Title
HK1050321A1 (en) Treatment of cartilage disorders
HK1047755A1 (zh) 胰島素樣生長因子激動肽的用途
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ATE297202T1 (de) Verwendung von nichtimmununterdruckende verbindungen zur förderung von nervenregeneration
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
EP0832973A3 (en) GTP-binding protein
SI1095140T1 (sl) Nevrotrofični dejavniki
EP0477971A3 (en) Human cnp gene and precursor protein
HK1026215A1 (en) Analogs of parathyroid hormone
AU3498189A (en) Fibronectin binding protein
IL115792A0 (en) Al-1 neurothophic factor
GB0202556D0 (en) Novel Protein
WO2007030519A3 (en) Stabilized glp-1 analogs
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
AU3793493A (en) Therapeutic domains of von willebrand factor
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ES2072868T3 (es) Proteina capaz de unir la fibronectina y su preparacion.
PT781341E (pt) Processo para a produção de proteínas recombinantes, plasmídeos e células modificadas
GB9509557D0 (en) PCNA binding substance
HUT64369A (en) Collagen binding protein and method for producing it
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
GB9416536D0 (en) Orphan receptor
DK0923644T3 (da) G-koblet receptor, der udviser selektiv selektivitet for ATP
EP0801133A3 (en) Hydroperoxide lyases
WO2001072826A3 (en) Oncogenic osteomalacia-related gene 1

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180516